{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:37:58Z","timestamp":1782139078611,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00415-025-13224-8","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T12:30:15Z","timestamp":1751113815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study"],"prefix":"10.1007","volume":"272","author":[{"given":"Tiziana","family":"Zaccone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Guerrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Nozzolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Scarale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola M. V.","family":"Rancoita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Clinical SanRaf MS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Azzimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Gueye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Margoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"3","key":"13224_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"3","key":"13224_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"issue":"10","key":"13224_CR3","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, Patti F, Pozzilli C, Preziosa P, Trojano M (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382\u20135394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w","journal-title":"J Neurol"},{"issue":"13","key":"13224_CR4","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL et al (2020) Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 95(13):e1854\u2013e1867. https:\/\/doi.org\/10.1212\/WNL.0000000000010376","journal-title":"Neurology"},{"issue":"12","key":"13224_CR5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B et al (2020) Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol 19(12):998\u20131009. https:\/\/doi.org\/10.1016\/S1474-4422(20)30342-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"13224_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/acn3.51732","volume":"10","author":"X Montalban","year":"2023","unstructured":"Montalban X, Matthews PM, Simpson A et al (2023) Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review. Ann Clin Transl Neurol 10(3):302\u2013311. https:\/\/doi.org\/10.1002\/acn3.51732","journal-title":"Ann Clin Transl Neurol"},{"key":"13224_CR7","unstructured":"Hauser SL, Giovannoni G, Filippi M et al (2024) The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the phase III OPERA and ORATORIO studies. In: Presented at the 40th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 18\u201320 September 2024; Copenhagen, Denmark"},{"issue":"11","key":"13224_CR8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"issue":"2","key":"13224_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","volume":"11","author":"DH Miller","year":"2012","unstructured":"Miller DH, Chard DT, Ciccarelli O (2012) Clinically isolated syndromes. Lancet Neurol 11(2):157\u2013169. https:\/\/doi.org\/10.1016\/S1474-4422(11)70274-5","journal-title":"Lancet Neurol"},{"issue":"Pt 9","key":"13224_CR10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V et al (2016) Defining secondary progressive multiple sclerosis. Brain 139(Pt 9):2395\u20132405. https:\/\/doi.org\/10.1093\/brain\/aww173","journal-title":"Brain"},{"issue":"9","key":"13224_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132\u20131140. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568","journal-title":"JAMA Neurol"},{"issue":"9","key":"13224_CR12","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1111\/ene.15891","volume":"30","author":"S Guerrieri","year":"2023","unstructured":"Guerrieri S, Bucca C, Nozzolillo A et al (2023) Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience. Eur J Neurol 30(9):2859\u20132864. https:\/\/doi.org\/10.1111\/ene.15891","journal-title":"Eur J Neurol"},{"key":"13224_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105570","volume":"86","author":"L Diem","year":"2024","unstructured":"Diem L, Ovchinnikov A, Friedli C et al (2024) Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss multiple sclerosis centers. Mult Scler Relat Disord 86:105570. https:\/\/doi.org\/10.1016\/j.msard.2024.105570","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"13224_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/13524585241309835","volume":"31","author":"A Del Canto","year":"2025","unstructured":"Del Canto A, C\u00e1rcamo C, Garcia L et al (2025) Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis. Mult Scler 31(4):444\u2013454. https:\/\/doi.org\/10.1177\/13524585241309835","journal-title":"Mult Scler"},{"key":"13224_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105776","volume":"89","author":"M Krbot Skori\u0107","year":"2024","unstructured":"Krbot Skori\u0107 M, Ba\u0161i\u0107 Kes V, Grbi\u0107 N et al (2024) Ocrelizumab in people with primary progressive multiple sclerosis: a real-world multicentric study. Mult Scler Relat Disord 89:105776. https:\/\/doi.org\/10.1016\/j.msard.2024.105776","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"13224_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/21556660.2021.1989193","volume":"10","author":"B Garcia-Ca\u00f1ibano","year":"2021","unstructured":"Garcia-Ca\u00f1ibano B, Ouanes S, Ganesan GS et al (2021) Real-world experience of ocrelizumab in multiple sclerosis in an Arab population. J Drug Assess 10(1):106\u2013113. https:\/\/doi.org\/10.1080\/21556660.2021.1989193","journal-title":"J Drug Assess"},{"issue":"8","key":"13224_CR17","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s10072-024-07449-0","volume":"45","author":"L Lorefice","year":"2024","unstructured":"Lorefice L, Mellino P, Frau J, Coghe G, Fenu G, Cocco E (2024) Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. Neurol Sci 45(8):3951\u20133959. https:\/\/doi.org\/10.1007\/s10072-024-07449-0","journal-title":"Neurol Sci"},{"issue":"4","key":"13224_CR18","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","volume":"18","author":"M Cellerino","year":"2021","unstructured":"Cellerino M, Boffa G, Lapucci C et al (2021) Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Neurotherapeutics 18(4):2579\u20132588. https:\/\/doi.org\/10.1007\/s13311-021-01104-8","journal-title":"Neurotherapeutics"},{"issue":"16","key":"13224_CR19","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X et al (2021) Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology 97(16):e1546\u2013e1559. https:\/\/doi.org\/10.1212\/WNL.0000000000012700","journal-title":"Neurology"},{"issue":"4","key":"13224_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s13760-024-02572-3","volume":"124","author":"T Erdogan","year":"2024","unstructured":"Erdogan T, Cansu C, Kocer B, Akkaya S, Kokmen H (2024) Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up. Acta Neurol Belg 124(4):1385\u20131391. https:\/\/doi.org\/10.1007\/s13760-024-02572-3","journal-title":"Acta Neurol Belg"},{"issue":"9","key":"13224_CR21","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00415-020-09913-1","volume":"267","author":"S Lopez-Leon","year":"2020","unstructured":"Lopez-Leon S, Geissb\u00fchler Y, Sabid\u00f3 M, Turkson M, Wahlich C, Morris JK (2020) A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. J Neurol 267(9):2721\u20132731. https:\/\/doi.org\/10.1007\/s00415-020-09913-1","journal-title":"J Neurol"},{"key":"13224_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105306","volume":"80","author":"K Hellwig","year":"2023","unstructured":"Hellwig K, Oreja-Guevara C, Vukusic S et al (2023) Pregnancy and infant outcomes in women receiving ocrelizumab for the treatment of multiple sclerosis: analysis of the largest available outcomes database. Mult Scler Relat Disord 80:105306. https:\/\/doi.org\/10.1016\/j.msard.2023.105306","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"13224_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200349","volume":"12","author":"S Vukusic","year":"2025","unstructured":"Vukusic S, Bove R, Dobson R et al (2025) Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab. Neurol Neuroimmunol Neuroinflamm 12(1):e200349. https:\/\/doi.org\/10.1212\/NXI.0000000000200349","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13224-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T06:26:04Z","timestamp":1752301564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13224-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["13224"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13224-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests in relation to this work. Potential conflicts of interest outside the submitted work are as follows: TZ has nothing to disclose. LM received compensations for speaking activities and\/or for participating to advisory board from Merck, Celgene, Biogen, Sanofi, Novartis, Roche, Alexion, and Amgen. SG received compensation for speaking activities from Bristol Squibb Meyer, Novartis, Merck. AN has nothing to disclose. CZ received compensation for speaking activities, and\/or consulting services, from Alexion, AstraZeneca, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi. IG has nothing to disclose. AG received compensation for speaking activities from Novartis. FE received consulting and speaking fees from Novartis and Sanofi Genzyme. MGS has nothing to disclose. PMVR has nothing to disclose. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Roche; and speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Celgene, Horizon Therapeutics Italy, Merck Serono SpA, Mitsubishi-Tanabe Pharma, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders; and Associate Co-Editor for Europe and Africa for Multiple Sclerosis Journal. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Approval was received from the institutional ethical standards committee on human experimentation of IRCCS Ospedale San Raffaele for any experiments using human subjects. Written informed consent was obtained from all subjects prior to study participation according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}],"article-number":"481"}}